» Articles » PMID: 38526664

Cuminaldehyde and Tobramycin Forestall the Biofilm Threats of Staphylococcus Aureus: A Combinatorial Strategy to Evade the Biofilm Challenges

Abstract

Staphylococcus aureus, an opportunistic Gram-positive pathogen, is known for causing various infections in humans, primarily by forming biofilms. The biofilm-induced antibiotic resistance has been considered a significant medical threat. Combinatorial therapy has been considered a reliable approach to combat antibiotic resistance by using multiple antimicrobial agents simultaneously, targeting bacteria through different mechanisms of action. To this end, we examined the effects of two molecules, cuminaldehyde (a natural compound) and tobramycin (an antibiotic), individually and in combination, against staphylococcal biofilm. Our experimental observations demonstrated that cuminaldehyde (20 μg/mL) in combination with tobramycin (0.05 μg/mL) exhibited efficient reduction in biofilm formation compared to their individual treatments (p < 0.01). Additionally, the combination showed an additive interaction (fractional inhibitory concentration value 0.66) against S. aureus. Further analysis revealed that the effective combination accelerated the buildup of reactive oxygen species (ROS) and increased the membrane permeability of the bacteria. Our findings also specified that the cuminaldehyde in combination with tobramycin efficiently reduced biofilm-associated pathogenicity factors of S. aureus, including fibrinogen clumping ability, hemolysis property, and staphyloxanthin production. The selected concentrations of tobramycin and cuminaldehyde demonstrated promising activity against the biofilm development of S. aureus on catheter models without exerting antimicrobial effects. In conclusion, the combination of tobramycin and cuminaldehyde presented a successful strategy for combating staphylococcal biofilm-related healthcare threats. This combinatorial approach holds the potential for controlling biofilm-associated infections caused by S. aureus.

Citing Articles

Vitamin D3 potentiates antimicrobial and antibiofilm activities of streptomycin and thymoquinone against Pseudomonas aeruginosa.

Biswas P, Bose S, Chakraborty S World J Microbiol Biotechnol. 2025; 41(3):104.

PMID: 40074989 DOI: 10.1007/s11274-025-04304-y.


Development of novel strategies against the threats of drug-resistant : an in silico and in vitro investigation.

Maity A, Das A, Roy R, Malik M, Das S, Paul P 3 Biotech. 2025; 15(4):77.

PMID: 40060287 PMC: 11885756. DOI: 10.1007/s13205-025-04246-0.


Combinatorial Effects of Ursodeoxycholic Acid and Antibiotic in Combating Biofilm: The Roles of ROS and Virulence Factors.

Tyagi A, Kumar V, Joshi N, Dhingra H Microorganisms. 2024; 12(10).

PMID: 39458266 PMC: 11509559. DOI: 10.3390/microorganisms12101956.

References
1.
Chakraborty P, Dastidar D, Paul P, Dutta S, Basu D, Sharma S . Inhibition of biofilm formation of Pseudomonas aeruginosa by caffeine: a potential approach for sustainable management of biofilm. Arch Microbiol. 2019; 202(3):623-635. DOI: 10.1007/s00203-019-01775-0. View

2.
Khan F, Lee J, Pham D, Lee J, Kim H, Kim Y . Streptomycin mediated biofilm inhibition and suppression of virulence properties in Pseudomonas aeruginosa PAO1. Appl Microbiol Biotechnol. 2019; 104(2):799-816. DOI: 10.1007/s00253-019-10190-w. View

3.
Gupta P, Sarkar S, Das B, Bhattacharjee S, Tribedi P . Biofilm, pathogenesis and prevention--a journey to break the wall: a review. Arch Microbiol. 2015; 198(1):1-15. DOI: 10.1007/s00203-015-1148-6. View

4.
Paul P, Roy R, Das S, Sarkar S, Chatterjee S, Mallik M . The combinatorial applications of 1,4-naphthoquinone and tryptophan inhibit the biofilm formation of Staphylococcus aureus. Folia Microbiol (Praha). 2023; 68(5):801-811. DOI: 10.1007/s12223-023-01054-y. View

5.
Goel N, Fatima S, Kumar S, Sinha R, Khare S . Antimicrobial resistance in biofilms: Exploring marine actinobacteria as a potential source of antibiotics and biofilm inhibitors. Biotechnol Rep (Amst). 2021; 30:e00613. PMC: 8105627. DOI: 10.1016/j.btre.2021.e00613. View